Drug-induced immune thrombocytopenic purpura secondary to sunitinib

Sunitinib (Sutent: Pfizer, New York, NY, U.S.A.) is an oral multi-targeted tyrosine kinase inhibitor approved for use in various solid tumour malignancies. Many side effects secondary to sunitinib have been documented. In particular, sunitinib administration is known to result in thrombocytopenia, w...

Descripción completa

Detalles Bibliográficos
Autores principales: Trinkaus, M., Trudeau, M., Callum, J.
Formato: Texto
Lenguaje:English
Publicado: Multimed Inc. 2008
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2442762/
https://www.ncbi.nlm.nih.gov/pubmed/18596889
_version_ 1782156728526176256
author Trinkaus, M.
Trudeau, M.
Callum, J.
author_facet Trinkaus, M.
Trudeau, M.
Callum, J.
author_sort Trinkaus, M.
collection PubMed
description Sunitinib (Sutent: Pfizer, New York, NY, U.S.A.) is an oral multi-targeted tyrosine kinase inhibitor approved for use in various solid tumour malignancies. Many side effects secondary to sunitinib have been documented. In particular, sunitinib administration is known to result in thrombocytopenia, with the cause being attributed to myelosuppression. Here, we present the first case report to demonstrate immune-mediated thrombocytopenia secondary to sunitinib administration.
format Text
id pubmed-2442762
institution National Center for Biotechnology Information
language English
publishDate 2008
publisher Multimed Inc.
record_format MEDLINE/PubMed
spelling pubmed-24427622008-07-02 Drug-induced immune thrombocytopenic purpura secondary to sunitinib Trinkaus, M. Trudeau, M. Callum, J. Curr Oncol Case Report Sunitinib (Sutent: Pfizer, New York, NY, U.S.A.) is an oral multi-targeted tyrosine kinase inhibitor approved for use in various solid tumour malignancies. Many side effects secondary to sunitinib have been documented. In particular, sunitinib administration is known to result in thrombocytopenia, with the cause being attributed to myelosuppression. Here, we present the first case report to demonstrate immune-mediated thrombocytopenia secondary to sunitinib administration. Multimed Inc. 2008-06 /pmc/articles/PMC2442762/ /pubmed/18596889 Text en 2008 Multimed Inc.
spellingShingle Case Report
Trinkaus, M.
Trudeau, M.
Callum, J.
Drug-induced immune thrombocytopenic purpura secondary to sunitinib
title Drug-induced immune thrombocytopenic purpura secondary to sunitinib
title_full Drug-induced immune thrombocytopenic purpura secondary to sunitinib
title_fullStr Drug-induced immune thrombocytopenic purpura secondary to sunitinib
title_full_unstemmed Drug-induced immune thrombocytopenic purpura secondary to sunitinib
title_short Drug-induced immune thrombocytopenic purpura secondary to sunitinib
title_sort drug-induced immune thrombocytopenic purpura secondary to sunitinib
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2442762/
https://www.ncbi.nlm.nih.gov/pubmed/18596889
work_keys_str_mv AT trinkausm druginducedimmunethrombocytopenicpurpurasecondarytosunitinib
AT trudeaum druginducedimmunethrombocytopenicpurpurasecondarytosunitinib
AT callumj druginducedimmunethrombocytopenicpurpurasecondarytosunitinib

Ejemplares similares